Navigation Links
Humanized Antibody Therapy Found Highly Effective in Easing RA Symptoms

Medical University of Vienna researchers have shown that nearly half of patients with rheumatoid arthritis (RA), who receive tocilizumab in addition to ongoing methotrexate therapy , showed a 50 per cent improvement in the symptoms at 24 weeks.

Also one fifth of the patients achieved a 70 per cent improvement in symptoms in the same period during the study, which was presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona.

These data show the potential of tocilizumab as a novel and attractive approach to treating RA. The symptom improvements observed across both 4mg/kg and 8mg/kg doses show that tocilizumab offers significant promise to patients with moderate and severe RA, said lead researcher Dr. Josef Smolen.

The researchers say that significant improvement in symptoms was observed in all patients receiving tocilizumab and methotrexate, compared to placebo and methotrexate.

They observed that 79.5 per cent of patients receiving tocilizumab 8mg/kg, and 61.9 per cent receiving 4mg/kg tocilizumab had achieved a good/moderate EULAR response, in comparison with placebo subjects.

A reduction in Disease Activity Score was also observed from two weeks onwards in both tocilizumab groups, say the researchers.

The study involved 623 patients with sustained moderate to severe RA despite long standing treatment with methotrexate. The subjects were permitted concurrent treatment with methotrexate at their pre-study dose, though treatment with all other disease modifying anti-rheumatic drugs was discontinued at the beginning of the trial.

Tocilizumab is a novel humanised anti human interleukin 6 (IIL-6) receptor monoclonal antibody, a cytokine involved in the pathogenesis of RA.


'"/>




Page: 1

Related medicine news :

1. Human Antibody That Can Block SARS
2. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
3. Cuba Registers New Antibody
4. Single Sugar Enables Antibody to Treat Inflammation
5. Monoclonal Antibody based system for Anthrax detection
6. Monoclonal Antibody Reduces Exacerbations in Asthmatics
7. Anti-rejection Therapy a Boon for Patients With "anti-donor" Antibody Levels
8. Antibody Therapy Prevents Type 1 Diabetes
9. New Antibody for EGFR Causes Lung Cancer Regression
10. J591- an Antibody Exclusively Targets Tumors
11. Antibody-based Therapies Effective at Controlling Malaria
Post Your Comments:
(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2
...c Health suggests that obesity can//increase the r...dy existing. Obesity had been conclusively associa... diabetes, and certain forms of cancer. This is fo...ns have been established between obesity and asthm...
...entists its said that it is better// to go for sur...to wait and see if the disease progresses. Surgery...atectomy, is a common procedure. The researchers h...tectomy done in early stages of prostate cancer be...
... gastro esophageal reflux may be due// to wrong ea.... Nocturnal heartburns often lead to disturbed sle...part from being cause of other disease. Nocturnal ...is often linked with severe form of gastro esophag...
...ce that sheds new light on the details of how Hunt...patient. Huntington's disease is a genetic disorde...o think or move on his own. Early symptoms of the ..., forgetfulness, and inability to concentrate or r...
Other Medicine News:
(Date:9/4/2008)...RNewswire-FirstCall/ -- BioForm Medical,Inc. (Nas...ical study of,Polidocanol, conducted in Germany by...SLER & Co. GmbH (Kreussler), successfully met the ...DA as part of a New Drug Application,(NDA) process...(Efficacy and safety of,Aethoxysklerol compared to...
(Date:9/4/2008)...0 Women at More Than 100 Sites in the U.S., ANN A...ceuticals, a,privately-held biopharmaceutical comp...f compounds to treat endocrine, metabolic and,card...initiated a second,Phase 3 clinical trial of Ophen...-free oral therapy in development for the treatmen...
(Date:9/4/2008)...chedule with Two Abstracts Accepted for Presen...r 2008, BRIDGEWATER, N.J., Sept. 4 /...maceutical company focused on the treatment of,car... the appointment of,Peter L. Garrambone, Jr. to th...,s career includes more than 50 pharmaceutical,tra...
(Date:9/3/2008)... from chronically infected Hepatitis C,patients st...arlier in 2008, - Study is the first to show a s...viral effect of therapeutic Hepatitis C vaccinatio... into a second generation, vaccine formulated wit... activation, VIENNA,...
Breaking Medicine Technology:338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 2338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 3338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 4338 Patient Pivotal Trial Demonstrates Safety and Effectiveness of Polidocanol Sclerotherapy Product for Varicose Vein Treatment 5QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 2QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 3Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4Millennium Biotechnologies Group Inc 28MBTG OB 29 Announces Appointment of Mark C Mirken as its President and Chief Operating Officer 525 1Millennium Biotechnologies Group Inc 28MBTG OB 29 Announces Appointment of Mark C Mirken as its President and Chief Operating Officer 525 2Millennium Biotechnologies Group Inc 28MBTG OB 29 Announces Appointment of Mark C Mirken as its President and Chief Operating Officer 525 3Tamoxifen Helps Treat Bipolar Disorder 1086 1Tamoxifen Helps Treat Bipolar Disorder 1086 2Tamoxifen Helps Treat Bipolar Disorder 1086 3Putting stem cell research on the fast track 359 1Putting stem cell research on the fast track 359 2Putting stem cell research on the fast track 359 3Putting stem cell research on the fast track 359 4Ken Sperling to Lead CIGNA HealthCare Retiree Solutions Unit 1079 1Ken Sperling to Lead CIGNA HealthCare Retiree Solutions Unit 1079 2
...ESS WIRE)--Apr 12, 2007 - Affymax, Inc.,(Nasdaq:AF...s Phase,2 clinical trial of Hematide(TM) dosed mon... at the National Kidney Foundation (NKF),2007 Spri...ance-switch trial in patients previously treated w...ated that mean,hemoglobin (Hgb) levels can be main...
...The costs of eradicating,poliomyelitis from the re...t term, are much lower than the long term costs of... And a recently developed,monovalent vaccine is al...iomyelitis than an existing trivalent vaccine. The...ne and in an upcoming,issue of The Lancet. , Both ...
Other Medicine Technology:Affymax Announces Results From Phase 2 Clinical Trial of Hematide,for the Treatment of Anemia in Dialysis Patients 2Affymax Announces Results From Phase 2 Clinical Trial of Hematide,for the Treatment of Anemia in Dialysis Patients 3Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying,to Control It Later 2Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying,to Control It Later 3
Rhoton Curettes, titanium, length 191 mm, straight.
Castroviejo "HM" Micro Needle Holder with Tungsten-Carbide Inserts, with catch. Serrated.
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface.
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface.
Medicine Products: